Latest Market News

Associate Global Partners lifted funds under management 20% to $1.672 billion in FY2026, powered by $172 million of net inflows and stronger WCM performance. The funds platform remains loss-making, but adjusted losses narrowed and post-year-end inflows began strongly.

Euroz Hartleys has appointed Alan Logan as CEO and unveiled a reshaped board as it prepares to complete the BMO transaction and focus on private wealth. Jay Hughes will return as chairman, while two current advisers will join the board as executive directors.

Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.

Austco Healthcare is pursuing its largest acquisition to date, combining a real-time monitoring software business with an aged care nurse call specialist in a deal worth up to an estimated $19.3 million. The transactions would add debt, recurring revenue and integration risk as the company expands beyond its core Tacera platform.

Sparc Technologies has signed a non-exclusive MoU with UK graphene producer Levidian Nanosystems to develop and commercialise ecosparc-enhanced coatings across the GCC. The agreement sets targets for a binding commercial deal within 12 months and potential UAE manufacturing within 24 months, but commits neither sales nor revenue.

Coventry Group’s Q1 FY27 EBITDA nearly doubled to A$5.4 million as cost reductions and margin gains began to outweigh modest sales growth. Leverage has also halved from its March peak, although the strategic review has yet to produce a transaction.

Vysarn delivered another year of rapid earnings growth, with revenue rising 31% and net profit after tax climbing 41% to $15.11 million. The bigger test now is whether its $65.3 million capital raise and Welltech acquisition can turn a growing collection of water businesses into a genuinely national platform.

Australian Vintage has returned to positive operating cash flow, but its FY26 statutory loss widened sharply after a $27 million inventory write-down and deferred tax charge. The wine group is betting that Poco Vino growth, further restructuring and lower stock levels can convert the cash improvement into debt reduction in FY27.

InFocus Group has signed its first Codexa ROW customer, with a conditional agreement that could deliver at least USD 2.4 million over 24 months. The company must first build and validate a prediction markets module, secure regulatory readiness and complete the customer's licensing and SPV arrangements.

Deep Yellow has withdrawn its target for a fourth-quarter 2026 Final Investment Decision on the Tumas uranium project, citing weak equity market conditions and constrained funding options. Construction continues, but the company has not provided a revised FID date or funding structure.

Vitura Health grew FY2026 revenue 6% to $131.2 million, but a sharp margin squeeze pushed the ASX-listed digital health company into a $4.4 million statutory loss. With ANZ debt classified as current and a potential $6 million FY2027 revenue hit from changed Bupa referrals, the promised turnaround faces a demanding test.

Zip Co will ask shareholders to approve a five-for-one share consolidation at its 19 November AGM, reducing its ordinary shares from about 1.246 billion to 249.2 million on an indicative basis. The move is designed to reshape the company’s capital structure, not alter the underlying value of investors’ holdings.